ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth
ADAR1 Capital Management, the largest shareholder of Keros Therapeutics (NASDAQ: KROS) with a 13.3% stake, has released an investor presentation detailing its reasons for opposing the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the company's Board of Directors. The decision will be voted on at Keros' Annual Meeting of Stockholders scheduled for June 4, 2025.
ADAR1 Capital Management, il maggiore azionista di Keros Therapeutics (NASDAQ: KROS) con una quota del 13,3%, ha pubblicato una presentazione per gli investitori in cui spiega le ragioni per cui si oppone alla rielezione di Dr.ssa Mary Ann Gray e Dr.ssa Alpna Seth nel Consiglio di Amministrazione della società. La decisione sarà votata durante l'Assemblea Annuale degli Azionisti di Keros, prevista per il 4 giugno 2025.
ADAR1 Capital Management, el mayor accionista de Keros Therapeutics (NASDAQ: KROS) con una participación del 13,3%, ha publicado una presentación para inversores detallando sus razones para oponerse a la reelección de la Dra. Mary Ann Gray y la Dra. Alpna Seth en el Consejo de Administración de la empresa. La decisión se votará en la Junta Anual de Accionistas de Keros programada para el 4 de junio de 2025.
ADAR1 Capital Management는 Keros Therapeutics (NASDAQ: KROS)의 최대 주주로서 13.3%의 지분을 보유하고 있으며, Dr. Mary Ann Gray와 Dr. Alpna Seth의 이사회 재선임에 반대하는 이유를 투자자 프레젠테이션을 통해 공개했습니다. 이 안건은 2025년 6월 4일에 예정된 Keros 주주총회에서 표결될 예정입니다.
ADAR1 Capital Management, principal actionnaire de Keros Therapeutics (NASDAQ : KROS) avec une participation de 13,3%, a publié une présentation aux investisseurs exposant ses raisons de s'opposer à la réélection de Dr Mary Ann Gray et Dr Alpna Seth au conseil d'administration de la société. Cette décision sera soumise au vote lors de l'assemblée générale annuelle des actionnaires de Keros prévue le 4 juin 2025.
ADAR1 Capital Management, der größte Aktionär von Keros Therapeutics (NASDAQ: KROS) mit einem Anteil von 13,3%, hat eine Investorenpräsentation veröffentlicht, in der die Gründe für die Ablehnung der Wiederwahl von Dr. Mary Ann Gray und Dr. Alpna Seth in den Vorstand des Unternehmens dargelegt werden. Die Entscheidung wird auf der Hauptversammlung der Aktionäre von Keros am 4. Juni 2025 zur Abstimmung stehen.
- None.
- None.
The presentation can be viewed here.
About ADAR1 Capital Management
ADAR1 Capital Management is an SEC-registered investment manager based in
Forward-Looking Statements
Certain financial projections and statements made in this press release and accompanying letter have been derived or obtained from filings made with the Securities and Exchange Commission ("SEC") or other regulatory authorities and from other third-party reports. Neither ADAR1 nor any of its affiliates shall be responsible or have any liability for any misinformation contained in any third-party SEC or other regulatory filing or third-party report. Select figures presented in this press release and accompanying letter have not been calculated using generally accepted accounting principles ("GAAP") and have not been audited by independent accountants. Such figures may vary from GAAP accounting in material respects and there can be no assurance that the unrealized values reflected within such materials will be realized. Nothing in this press release and accompanying letter is intended to be a prediction of the future trading price or market value of securities of the Company. Words such as "anticipate", "believe", "could", "estimate", "expect", "may", "ought to", "plan", "project", "seek", "should", "will", "would" and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Reliance on any forward-looking statements involves known and unknown risks and uncertainties and there is no assurance or guarantee that actual results or performance of the Company will not differ, and such differences may be material. In addition, there can be no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. The estimates, projections and potential impact of the opportunities identified by ADAR1 herein are based on assumptions that ADAR1 believes to be reasonable as of the date of this press release.
Contact:
info@adar1.com
512-254-3790
View original content to download multimedia:https://www.prnewswire.com/news-releases/adar1-capital-management-releases-investor-presentation-outlining-its-rationale-for-withholding-votes-from-directors-dr-mary-ann-gray-and-dr-alpna-seth-302452575.html
SOURCE ADAR1 Capital Management LLC
FAQ
Why is ADAR1 Capital Management opposing Keros Therapeutics (KROS) board members?
What percentage of Keros Therapeutics (KROS) does ADAR1 Capital Management own?
When is Keros Therapeutics (KROS) 2025 Annual Meeting of Stockholders?
Which Keros Therapeutics (KROS) board members are facing opposition from ADAR1?
